Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on the reduction of urge urinary incontinence episodes (and the resulting improvement in a patient's quality of life) is the attribute that most influences urologists' prescribing decisions in the treatment of urge urinary incontinence. Clinical data and expert opinion show that Astellas/GlaxoSmithKline's Vesicare has advantages in this attribute over the market sales leader, Pfizer's Detrol LA/ Detrusitol XL.
The new report entitled Urge Urinary Incontinence: Commercial Windfall Awaits the Treatment That Offers Significant Improvement in Dryness Rates finds that a drug offering a greater reduction in the number of urge urinary incontinence episodes per week over Detrol LA/Detrusitol XL would earn a 25 percent patient share in this market. The report also finds that, although Detrol LA/Detrusitol XL is the sales leader in the urge urinary market, the current and future gold standard treatment for the indication is Vesicare.
At doses that provide superior efficacy, clinical data and expert opinion indicate that Vesicare is superior to Detrol LA/Detrusitol XL and its successor, Pfizer's Toviaz, in its side-effect profile -- particularly on rates of dry mouth, an important cause for discontinuation of therapy.
"We do not expect any therapy under development for urge urinary incontinence to displace Vesicare as the clinical gold standard treatment," said Cindy Mundy, Ph.D., principal director at Decision Resources. "While some therapies in development for this indication hold promise, most of them earned inferior scores in efficacy, safety and tolerability, and/or delivery features when compared with Vesicare."
About the Report
Urge Urinary Incontinence: Commercial Windfall Awaits the Treatment That Offers Significant Improvement in Dryness Rates is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/